# ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure

> **NCT05117736** · NA · TERMINATED · sponsor: **Montreal Heart Institute** · enrollment: 15 (actual)

## Conditions studied

- Systemic Right Ventricle
- Heart Failure

## Interventions

- **DRUG:** Sacubitril / Valsartan Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05117736
- **Lead sponsor:** Montreal Heart Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-15
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-03-12
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The trial was prematurely terminated due to safety concerns.
- **Last updated:** 2024-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05117736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05117736, "ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05117736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*